Axial • 7 implied HN points • 13 Mar 24
- Kidney disease, particularly autosomal dominant polycystic kidney disease (PKD), has been underinvested compared to other conditions like oncology and diabetes.
- The development of drugs targeting GPCRs PC-1 and PC-2 in PKD could significantly improve the quality of life for patients by reducing cyst size.
- Business models in drug development are shifting towards rare disease candidates like PC-1/2, emphasizing treatments that exceed the current standard of care.